COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
25/06/2024
ASHBURN, Va., June 25, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
25/06/2024
– AK006 achieved serum concentrations consistent with levels demonstrating inhibitory activity in preclinical experiments – – Skin biopsies from subjects treated with AK006 show high receptor occupancy – – AK006 was [...]
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform
25/06/2024
First-ever clinical data demonstrating redosing with an investigational in vivo CRISPR-based therapy Follow-on dosing with a 55 mg dose of NTLA-2001 led to a 90% median reduction in serum TTR at day 28 in the three [...]
Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion
25/06/2024
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, [...]
SAFE - Finalisation des plans de redressement - Reports de l’Assemblée Générale annuelle 2024 et de la publication du rapport financier annuel 2023
25/06/2024
Finalisation des plans de redressement Reports de l’Assemblée Générale annuelle 2024 et de la publication du rapport financier annuel 2023 Fleurieux-sur-l’Arbresle - France - le 25 juin 2024 à 20h . Safe (FR001400F1V2 [...]
Press Release: Availability of the Q2 2024 Aide-mémoire
25/06/2024
Availability of the Q2 2024 Aide-mémoire Paris, France – June 25, 2024 . Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/ [...]
Communiqué de presse : Mise en ligne du document « Aide-mémoire Q2 2024 »
25/06/2024
Mise en ligne du document « Aide-mémoire Q2 2024 » Paris, France, le 25 juin 2024 . Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Aide-mémoire Q2 [...]
HFMA Announces Marc Scher as National Chair
25/06/2024
LAS VEGAS, June 25, 2024 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today during its annual conference inducted former KPMG LLP Partner Marc B. Scher, FHFMA, CPA, into office as its [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024
25/06/2024
Aggregated presentation by day and by market Purchases of own shares from June 17th to 21th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2024
25/06/2024
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 17 au 21 juin 2024 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
25/06/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority ( obere kantonale Nachlassbehörde [...]
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
25/06/2024
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN [...]
CORRECTION: Capricor Therapeutics
25/06/2024
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, [...]
Ursula Burns, former Xerox CEO, and Jordan Wertlieb, EVP and COO of Hearst, appointed to the Pediatric Brain Tumor Foundation’s Advisory Board as inaugural members
25/06/2024
Renowned business leaders Burns and Wertlieb to serve as special advisors to PBTF Board of Directors NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- The Pediatric Brain Tumor Foundation (PBTF) today announced the [...]
Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray
25/06/2024
Processed by PBIO’s Patented UltraShear Technology, this Revolutionary Product Combines Leading Potency Oil-Based Antioxidants (e.g., Acai, Curcumin, Astaxanthin, CoQ10, & More) into a Super-Fast Absorbing, Highly [...]
BlueSphere Bio To Partner with NMDP BioTherapies℠ for the Company’s First-In-Human TCR-based Product Candidate in Combination with Allogeneic Hematopoietic Cell Transplantation Trial
25/06/2024
Through this partnership, BlueSphere will treat patients with acute myeloid and lymphocytic leukemia, and myeloid dysplastic syndrome, who have active disease or are at high risk for relapse, with the goal of reducing [...]
MEDIROM Healthcare Technologies Inc. Announces Financial Results for Fiscal Year 2023
25/06/2024
TOKYO, June 25, 2024 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“Medirom” or the “Company”), a holistic healthcare company based in Japan, announced it filed its Annual Report on Form 20-F [...]
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
25/06/2024
HOUSTON, June 25, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development of [...]
Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance
25/06/2024
Twelve Required Registration Batches Completed New Drug Application Being Prepped for Submission KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) [...]

Pages